Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors and DNA damaging agents (TSDs) that directly target the tumor microenvironment. Dr. Ranjit Bindra, Cybrexa’s chief scientific adviser, discusses the technology that they hope will increase efficacy and decrease toxicity in cancer treatment.
David Heller, a vendor of health information technology, discusses the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) changes coming in 2019.
Dr. Adi Diab, M.D., Lead Trial Investigator, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, discusses the Idera Pharmaceuticals, Inc. presentation of data from the ongoing ILLUMINATE-204 trial investigating tilsotolimod in combination with ipilimumab (Yervoy®).
Dr. Brian Mech, Ph.D discusses eSight – the creators of electronic glasses that enable the legally blind to actually see again. eSight is worn like a normal pair of glasses, but it houses a high-speed, high-definition camera that captures everything you are looking at, and then displays it on two near-to-eye displays.
Dr. Larry Hirsch shares his personal story of having Type 1 Diabetes and how it motivated him to help others, offers expert advice to those who have diabetes and gives perspective on some of the most important advancements in diabetes management in recent years.
Jennifer Flynn, a representative from Nurses Service Organization (NSO), discusses sexual inappropriate behavior against nurses and other caregivers by patients.
Dr. Philip Salem, former White House Healthcare Advisor for Presidents George Bush and Bill Clinton, discusses his upcoming book, “Defeating Cancer: Knowledge Alone is Not Enough” – a new, comprehensive treatment guide for cancer patients and their loved ones.
Lead investigator, Dr. Ronald van Vollenhoven, M.D., Ph.D., talks about new, positive, one-year results from a continued Phase 2 study investigating STELARA® (ustekinumab) in the treatment of lupus at a plenary presentation at the 2018 ACR/ARHP Annual Meeting.
Dr. Bruce Sands from Mount Sinai discusses his presentation of the new pivotal Phase 3 data at the American College of Gastroenterology (ACG) Annual Scientific Meeting showing that a single IV dose of STELARA® (ustekinumab) – the first and only biologic targeting interleukin (IL)-12 and -23 cytokines – induced clinical remission in a greater percentage of adult patients with moderate-to-severe ulcerative colitis (UC), compared to those receiving placebo.
Retired pro ice hockey player Bryan Bickell talks about being diagnosed with relapsing multiple sclerosis. He is joined by his doctor, Timothy Vartanian, M.D., Ph.D., and MS expert, who talks more about relapsing MS, causes and symptoms, and the importance of early treatment. Both Bryan and Dr. Vartanian hope to encourage others impacted by MS to stay positive and keep fighting for their own goals. Bryan Bickell is a patient spokesperson for Biogen. Timothy Vartanian, M.D., Ph.D., is a paid spokesperson for Biogen.